- Home
- INTS vs DHIL Comparison
INTS vs DHIL Comparison
Compare INTS & DHIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- DHIL
- Stock Information
- Founded
- INTS 2012
- DHIL 1990
- Country
- INTS United States
- DHIL United States
- Employees
- INTS 16
- DHIL N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- DHIL Investment Managers
- Sector
- INTS Health Care
- DHIL Finance
- Exchange
- INTS Nasdaq
- DHIL Nasdaq
- Market Cap
- INTS 30.8M
- DHIL N/A
- IPO Year
- INTS 2023
- DHIL 1995
- Fundamental
- Price
- INTS $2.06
- DHIL $144.76
- Analyst Decision
- INTS Strong Buy
- DHIL
- Analyst Count
- INTS 3
- DHIL 0
- Target Price
- INTS $8.50
- DHIL N/A
- AVG Volume (30 Days)
- INTS 38.4K
- DHIL 15.9K
- Earning Date
- INTS 03-13-2025
- DHIL 04-29-2025
- Dividend Yield
- INTS N/A
- DHIL 4.15%
- EPS Growth
- INTS N/A
- DHIL 9.33
- EPS
- INTS N/A
- DHIL 15.66
- Revenue
- INTS N/A
- DHIL $151,095,131.00
- Revenue This Year
- INTS N/A
- DHIL N/A
- Revenue Next Year
- INTS N/A
- DHIL N/A
- P/E Ratio
- INTS N/A
- DHIL $9.12
- Revenue Growth
- INTS N/A
- DHIL 10.52
- 52 Week Low
- INTS $1.50
- DHIL $135.44
- 52 Week High
- INTS $5.28
- DHIL $173.25
- Technical
- Relative Strength Index (RSI)
- INTS 46.37
- DHIL 46.33
- Support Level
- INTS $1.88
- DHIL $142.08
- Resistance Level
- INTS $2.18
- DHIL $146.77
- Average True Range (ATR)
- INTS 0.21
- DHIL 1.88
- MACD
- INTS -0.01
- DHIL -0.05
- Stochastic Oscillator
- INTS 39.73
- DHIL 42.41
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.